Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons prof. dr. E.G.E. (Elisabeth) de Vries

Publicaties

Demystifying the WHO Model Lists of Essential Medicines for cancer care

Dose optimisation to improve access to effective cancer medicines

ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update

Heterogeneity of CD8 T-Cell Changes in Advanced Melanomas After Initiation of Immunotherapy

Integrating molecular imaging and transcriptomic profiling in advanced HER2-positive breast cancer receiving trastuzumab emtansine (T-DM1): an analysis of the ZEPHIR clinical trial

Intrapatient 16α-[18F]Fluoro-17β-Estradiol PET Heterogeneity as a Prognostic Factor for Endocrine Therapy Response and Survival in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.

Modelling the potential financial impacts of expanding access to immune checkpoint inhibitors as monotherapy for treating advanced non-small cell lung cancer

Transcriptional pattern enriched for synaptic signaling is associated with shorter survival of patients with high-grade serous ovarian cancer

Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)

128P - Whole blood transcriptomics identifies transcriptional patterns linked to outcomes in patients receiving immune checkpoint inhibitors

Pers/media

FORESIGHT doet onderzoek naar juiste patiënt en passende therapie

Major funding boost for molecular imaging in drug development

New consortium for immunotherapy research

FORESIGHT consortium encourages molecular imaging in developing new drugs

FORESIGHT consortium secures €9 million to fast-track drug development

Inschrijving 30e Oncologiedagen geopend

Van Laarhoven nieuw lid raad van toezicht IKNL

Whole-Body PET Scans Highlight Complexity of Immunotherapy Response